nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—prostate cancer	0.251	0.674	CbGaD
Gliclazide—CYP2C19—prostate cancer	0.122	0.326	CbGaD
Gliclazide—ALB—Abiraterone—prostate cancer	0.0443	0.135	CbGbCtD
Gliclazide—CYP2C19—Bicalutamide—prostate cancer	0.0347	0.105	CbGbCtD
Gliclazide—CYP2C19—Nilutamide—prostate cancer	0.0347	0.105	CbGbCtD
Gliclazide—ALB—Estrone—prostate cancer	0.032	0.0975	CbGbCtD
Gliclazide—CYP2C9—Nilutamide—prostate cancer	0.0288	0.0877	CbGbCtD
Gliclazide—CYP2C9—Bicalutamide—prostate cancer	0.0288	0.0877	CbGbCtD
Gliclazide—CYP2C19—Flutamide—prostate cancer	0.0287	0.0874	CbGbCtD
Gliclazide—ALB—Estradiol—prostate cancer	0.0184	0.056	CbGbCtD
Gliclazide—CYP2C9—Estrone—prostate cancer	0.0173	0.0525	CbGbCtD
Gliclazide—ALB—Prednisone—prostate cancer	0.0158	0.0481	CbGbCtD
Gliclazide—CYP2C9—Capecitabine—prostate cancer	0.0131	0.0398	CbGbCtD
Gliclazide—CYP2C19—Estradiol—prostate cancer	0.0119	0.0363	CbGbCtD
Gliclazide—CYP2C19—Prednisone—prostate cancer	0.0103	0.0312	CbGbCtD
Gliclazide—CYP2C9—Estradiol—prostate cancer	0.00992	0.0302	CbGbCtD
Gliclazide—ABCC8—penis—prostate cancer	0.00756	0.272	CbGeAlD
Gliclazide—CYP2C19—urine—prostate cancer	0.0029	0.105	CbGeAlD
Gliclazide—VEGFA—prostate gland—prostate cancer	0.00274	0.0988	CbGeAlD
Gliclazide—CYP2C9—urine—prostate cancer	0.00225	0.081	CbGeAlD
Gliclazide—VEGFA—urethra—prostate cancer	0.00184	0.0661	CbGeAlD
Gliclazide—ABCC8—prostate gland—prostate cancer	0.00181	0.0651	CbGeAlD
Gliclazide—ABCC8—seminal vesicle—prostate cancer	0.00153	0.055	CbGeAlD
Gliclazide—VEGFA—bone marrow—prostate cancer	0.00141	0.0509	CbGeAlD
Gliclazide—ABCC8—renal system—prostate cancer	0.00123	0.0444	CbGeAlD
Gliclazide—VEGFA—testis—prostate cancer	0.00121	0.0435	CbGeAlD
Gliclazide—VEGFA—lymph node—prostate cancer	0.000876	0.0315	CbGeAlD
Gliclazide—ABCC8—testis—prostate cancer	0.000796	0.0287	CbGeAlD
Gliclazide—VEGFA—Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.000745	0.262	CbGdCrCtD
Gliclazide—VEGFA—Estradiol—Estramustine—prostate cancer	0.000634	0.223	CbGdCrCtD
Gliclazide—KCNJ11—lymph node—prostate cancer	0.000626	0.0226	CbGeAlD
Gliclazide—ALB—testis—prostate cancer	0.00057	0.0205	CbGeAlD
Gliclazide—VEGFA—Estradiol—Estrone—prostate cancer	0.000503	0.177	CbGdCrCtD
Gliclazide—Tolbutamide—CYP2C18—prostate cancer	0.000444	0.354	CrCbGaD
Gliclazide—VEGFA—Estradiol—Conjugated Estrogens—prostate cancer	0.000443	0.156	CbGdCrCtD
Gliclazide—ALB—lymph node—prostate cancer	0.000413	0.0149	CbGeAlD
Gliclazide—VEGFA—Estradiol—Ethinyl Estradiol—prostate cancer	0.000372	0.131	CbGdCrCtD
Gliclazide—Chlorpropamide—CYP2C19—prostate cancer	0.000204	0.163	CrCbGaD
Gliclazide—Tolbutamide—CYP2C19—prostate cancer	0.000199	0.159	CrCbGaD
Gliclazide—Glipizide—CYP3A4—prostate cancer	0.00018	0.143	CrCbGaD
Gliclazide—Glyburide—CYP2C19—prostate cancer	0.000138	0.11	CrCbGaD
Gliclazide—Glyburide—CYP3A4—prostate cancer	8.78e-05	0.0701	CrCbGaD
Gliclazide—VEGFA—Dexamethasone—Prednisone—prostate cancer	7.28e-05	0.0256	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Prednisone—prostate cancer	7.28e-05	0.0256	CbGdCrCtD
Gliclazide—Conjunctivitis—Doxorubicin—prostate cancer	3.1e-05	0.000189	CcSEcCtD
Gliclazide—Urinary tract infection—Doxorubicin—prostate cancer	3.1e-05	0.000189	CcSEcCtD
Gliclazide—Nervous system disorder—Capecitabine—prostate cancer	3.09e-05	0.000189	CcSEcCtD
Gliclazide—Hepatitis—Epirubicin—prostate cancer	3.09e-05	0.000189	CcSEcCtD
Gliclazide—Thrombocytopenia—Capecitabine—prostate cancer	3.09e-05	0.000189	CcSEcCtD
Gliclazide—Tachycardia—Capecitabine—prostate cancer	3.08e-05	0.000188	CcSEcCtD
Gliclazide—Hypoaesthesia—Epirubicin—prostate cancer	3.07e-05	0.000188	CcSEcCtD
Gliclazide—Pharyngitis—Epirubicin—prostate cancer	3.07e-05	0.000187	CcSEcCtD
Gliclazide—Skin disorder—Capecitabine—prostate cancer	3.06e-05	0.000187	CcSEcCtD
Gliclazide—Sweating—Doxorubicin—prostate cancer	3.05e-05	0.000187	CcSEcCtD
Gliclazide—Hyperhidrosis—Capecitabine—prostate cancer	3.05e-05	0.000186	CcSEcCtD
Gliclazide—Oedema peripheral—Epirubicin—prostate cancer	3.04e-05	0.000186	CcSEcCtD
Gliclazide—Hypotension—Docetaxel—prostate cancer	3.04e-05	0.000186	CcSEcCtD
Gliclazide—Loss of consciousness—Prednisone—prostate cancer	3.02e-05	0.000185	CcSEcCtD
Gliclazide—Hepatobiliary disease—Doxorubicin—prostate cancer	3.01e-05	0.000184	CcSEcCtD
Gliclazide—Epistaxis—Doxorubicin—prostate cancer	3e-05	0.000184	CcSEcCtD
Gliclazide—Nausea—Estradiol—prostate cancer	3e-05	0.000183	CcSEcCtD
Gliclazide—Vomiting—Mitoxantrone—prostate cancer	2.99e-05	0.000183	CcSEcCtD
Gliclazide—Sinusitis—Doxorubicin—prostate cancer	2.99e-05	0.000183	CcSEcCtD
Gliclazide—Convulsion—Prednisone—prostate cancer	2.98e-05	0.000182	CcSEcCtD
Gliclazide—Visual impairment—Epirubicin—prostate cancer	2.98e-05	0.000182	CcSEcCtD
Gliclazide—Agranulocytosis—Doxorubicin—prostate cancer	2.97e-05	0.000182	CcSEcCtD
Gliclazide—Hypertension—Prednisone—prostate cancer	2.97e-05	0.000182	CcSEcCtD
Gliclazide—Rash—Mitoxantrone—prostate cancer	2.97e-05	0.000181	CcSEcCtD
Gliclazide—Dermatitis—Mitoxantrone—prostate cancer	2.97e-05	0.000181	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Docetaxel—prostate cancer	2.97e-05	0.000181	CcSEcCtD
Gliclazide—Headache—Mitoxantrone—prostate cancer	2.95e-05	0.00018	CcSEcCtD
Gliclazide—Hypotension—Capecitabine—prostate cancer	2.95e-05	0.00018	CcSEcCtD
Gliclazide—Insomnia—Docetaxel—prostate cancer	2.94e-05	0.00018	CcSEcCtD
Gliclazide—Myalgia—Prednisone—prostate cancer	2.93e-05	0.000179	CcSEcCtD
Gliclazide—Arthralgia—Prednisone—prostate cancer	2.93e-05	0.000179	CcSEcCtD
Gliclazide—Paraesthesia—Docetaxel—prostate cancer	2.92e-05	0.000179	CcSEcCtD
Gliclazide—Erythema multiforme—Epirubicin—prostate cancer	2.92e-05	0.000179	CcSEcCtD
Gliclazide—Anxiety—Prednisone—prostate cancer	2.92e-05	0.000178	CcSEcCtD
Gliclazide—Bradycardia—Doxorubicin—prostate cancer	2.91e-05	0.000178	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	2.91e-05	0.000178	CcSEcCtD
Gliclazide—Dyspnoea—Docetaxel—prostate cancer	2.9e-05	0.000177	CcSEcCtD
Gliclazide—Somnolence—Docetaxel—prostate cancer	2.89e-05	0.000177	CcSEcCtD
Gliclazide—Discomfort—Prednisone—prostate cancer	2.89e-05	0.000177	CcSEcCtD
Gliclazide—Eye disorder—Epirubicin—prostate cancer	2.89e-05	0.000177	CcSEcCtD
Gliclazide—Hypersensitivity—Etoposide—prostate cancer	2.89e-05	0.000176	CcSEcCtD
Gliclazide—Tinnitus—Epirubicin—prostate cancer	2.88e-05	0.000176	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Capecitabine—prostate cancer	2.87e-05	0.000176	CcSEcCtD
Gliclazide—Flushing—Epirubicin—prostate cancer	2.87e-05	0.000175	CcSEcCtD
Gliclazide—Rhinitis—Doxorubicin—prostate cancer	2.87e-05	0.000175	CcSEcCtD
Gliclazide—Dyspepsia—Docetaxel—prostate cancer	2.87e-05	0.000175	CcSEcCtD
Gliclazide—Hepatitis—Doxorubicin—prostate cancer	2.86e-05	0.000175	CcSEcCtD
Gliclazide—Insomnia—Capecitabine—prostate cancer	2.85e-05	0.000174	CcSEcCtD
Gliclazide—Hypoaesthesia—Doxorubicin—prostate cancer	2.85e-05	0.000174	CcSEcCtD
Gliclazide—Pharyngitis—Doxorubicin—prostate cancer	2.84e-05	0.000173	CcSEcCtD
Gliclazide—Paraesthesia—Capecitabine—prostate cancer	2.83e-05	0.000173	CcSEcCtD
Gliclazide—Oedema peripheral—Doxorubicin—prostate cancer	2.82e-05	0.000172	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Docetaxel—prostate cancer	2.81e-05	0.000172	CcSEcCtD
Gliclazide—Asthenia—Etoposide—prostate cancer	2.81e-05	0.000172	CcSEcCtD
Gliclazide—Dyspnoea—Capecitabine—prostate cancer	2.81e-05	0.000172	CcSEcCtD
Gliclazide—Fatigue—Docetaxel—prostate cancer	2.81e-05	0.000172	CcSEcCtD
Gliclazide—Nausea—Mitoxantrone—prostate cancer	2.8e-05	0.000171	CcSEcCtD
Gliclazide—Infection—Prednisone—prostate cancer	2.79e-05	0.00017	CcSEcCtD
Gliclazide—Constipation—Docetaxel—prostate cancer	2.78e-05	0.00017	CcSEcCtD
Gliclazide—Pain—Docetaxel—prostate cancer	2.78e-05	0.00017	CcSEcCtD
Gliclazide—Dyspepsia—Capecitabine—prostate cancer	2.77e-05	0.00017	CcSEcCtD
Gliclazide—Chills—Epirubicin—prostate cancer	2.77e-05	0.000169	CcSEcCtD
Gliclazide—Pruritus—Etoposide—prostate cancer	2.77e-05	0.000169	CcSEcCtD
Gliclazide—Arrhythmia—Epirubicin—prostate cancer	2.76e-05	0.000169	CcSEcCtD
Gliclazide—Visual impairment—Doxorubicin—prostate cancer	2.76e-05	0.000168	CcSEcCtD
Gliclazide—Nervous system disorder—Prednisone—prostate cancer	2.75e-05	0.000168	CcSEcCtD
Gliclazide—Tachycardia—Prednisone—prostate cancer	2.74e-05	0.000167	CcSEcCtD
Gliclazide—Skin disorder—Prednisone—prostate cancer	2.73e-05	0.000167	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Capecitabine—prostate cancer	2.72e-05	0.000166	CcSEcCtD
Gliclazide—Fatigue—Capecitabine—prostate cancer	2.72e-05	0.000166	CcSEcCtD
Gliclazide—Hyperhidrosis—Prednisone—prostate cancer	2.71e-05	0.000166	CcSEcCtD
Gliclazide—Mental disorder—Epirubicin—prostate cancer	2.71e-05	0.000165	CcSEcCtD
Gliclazide—Erythema multiforme—Doxorubicin—prostate cancer	2.7e-05	0.000165	CcSEcCtD
Gliclazide—Pain—Capecitabine—prostate cancer	2.7e-05	0.000165	CcSEcCtD
Gliclazide—Constipation—Capecitabine—prostate cancer	2.7e-05	0.000165	CcSEcCtD
Gliclazide—Erythema—Epirubicin—prostate cancer	2.69e-05	0.000164	CcSEcCtD
Gliclazide—Malnutrition—Epirubicin—prostate cancer	2.69e-05	0.000164	CcSEcCtD
Gliclazide—Feeling abnormal—Docetaxel—prostate cancer	2.68e-05	0.000164	CcSEcCtD
Gliclazide—Diarrhoea—Etoposide—prostate cancer	2.68e-05	0.000164	CcSEcCtD
Gliclazide—Eye disorder—Doxorubicin—prostate cancer	2.67e-05	0.000163	CcSEcCtD
Gliclazide—Tinnitus—Doxorubicin—prostate cancer	2.67e-05	0.000163	CcSEcCtD
Gliclazide—Gastrointestinal pain—Docetaxel—prostate cancer	2.66e-05	0.000163	CcSEcCtD
Gliclazide—Flushing—Doxorubicin—prostate cancer	2.65e-05	0.000162	CcSEcCtD
Gliclazide—Flatulence—Epirubicin—prostate cancer	2.65e-05	0.000162	CcSEcCtD
Gliclazide—Tension—Epirubicin—prostate cancer	2.64e-05	0.000161	CcSEcCtD
Gliclazide—Nervousness—Epirubicin—prostate cancer	2.61e-05	0.00016	CcSEcCtD
Gliclazide—Back pain—Epirubicin—prostate cancer	2.6e-05	0.000159	CcSEcCtD
Gliclazide—Feeling abnormal—Capecitabine—prostate cancer	2.6e-05	0.000159	CcSEcCtD
Gliclazide—Dizziness—Etoposide—prostate cancer	2.59e-05	0.000158	CcSEcCtD
Gliclazide—Gastrointestinal pain—Capecitabine—prostate cancer	2.58e-05	0.000158	CcSEcCtD
Gliclazide—Abdominal pain—Docetaxel—prostate cancer	2.57e-05	0.000157	CcSEcCtD
Gliclazide—Body temperature increased—Docetaxel—prostate cancer	2.57e-05	0.000157	CcSEcCtD
Gliclazide—Chills—Doxorubicin—prostate cancer	2.57e-05	0.000157	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Prednisone—prostate cancer	2.56e-05	0.000156	CcSEcCtD
Gliclazide—Arrhythmia—Doxorubicin—prostate cancer	2.55e-05	0.000156	CcSEcCtD
Gliclazide—Insomnia—Prednisone—prostate cancer	2.54e-05	0.000155	CcSEcCtD
Gliclazide—Paraesthesia—Prednisone—prostate cancer	2.52e-05	0.000154	CcSEcCtD
Gliclazide—Mental disorder—Doxorubicin—prostate cancer	2.51e-05	0.000153	CcSEcCtD
Gliclazide—Urticaria—Capecitabine—prostate cancer	2.5e-05	0.000153	CcSEcCtD
Gliclazide—Ill-defined disorder—Epirubicin—prostate cancer	2.5e-05	0.000153	CcSEcCtD
Gliclazide—Abdominal pain—Capecitabine—prostate cancer	2.49e-05	0.000152	CcSEcCtD
Gliclazide—Body temperature increased—Capecitabine—prostate cancer	2.49e-05	0.000152	CcSEcCtD
Gliclazide—Vomiting—Etoposide—prostate cancer	2.49e-05	0.000152	CcSEcCtD
Gliclazide—Erythema—Doxorubicin—prostate cancer	2.49e-05	0.000152	CcSEcCtD
Gliclazide—Malnutrition—Doxorubicin—prostate cancer	2.49e-05	0.000152	CcSEcCtD
Gliclazide—Anaemia—Epirubicin—prostate cancer	2.49e-05	0.000152	CcSEcCtD
Gliclazide—Agitation—Epirubicin—prostate cancer	2.47e-05	0.000151	CcSEcCtD
Gliclazide—Dyspepsia—Prednisone—prostate cancer	2.47e-05	0.000151	CcSEcCtD
Gliclazide—Rash—Etoposide—prostate cancer	2.47e-05	0.000151	CcSEcCtD
Gliclazide—Dermatitis—Etoposide—prostate cancer	2.47e-05	0.000151	CcSEcCtD
Gliclazide—Headache—Etoposide—prostate cancer	2.45e-05	0.00015	CcSEcCtD
Gliclazide—Flatulence—Doxorubicin—prostate cancer	2.45e-05	0.00015	CcSEcCtD
Gliclazide—Tension—Doxorubicin—prostate cancer	2.44e-05	0.000149	CcSEcCtD
Gliclazide—Malaise—Epirubicin—prostate cancer	2.43e-05	0.000148	CcSEcCtD
Gliclazide—Fatigue—Prednisone—prostate cancer	2.42e-05	0.000148	CcSEcCtD
Gliclazide—Nervousness—Doxorubicin—prostate cancer	2.42e-05	0.000148	CcSEcCtD
Gliclazide—Leukopenia—Epirubicin—prostate cancer	2.41e-05	0.000147	CcSEcCtD
Gliclazide—Back pain—Doxorubicin—prostate cancer	2.41e-05	0.000147	CcSEcCtD
Gliclazide—Constipation—Prednisone—prostate cancer	2.4e-05	0.000147	CcSEcCtD
Gliclazide—Hypersensitivity—Docetaxel—prostate cancer	2.4e-05	0.000147	CcSEcCtD
Gliclazide—Palpitations—Epirubicin—prostate cancer	2.38e-05	0.000145	CcSEcCtD
Gliclazide—Loss of consciousness—Epirubicin—prostate cancer	2.36e-05	0.000145	CcSEcCtD
Gliclazide—Cough—Epirubicin—prostate cancer	2.35e-05	0.000143	CcSEcCtD
Gliclazide—Asthenia—Docetaxel—prostate cancer	2.34e-05	0.000143	CcSEcCtD
Gliclazide—Convulsion—Epirubicin—prostate cancer	2.33e-05	0.000142	CcSEcCtD
Gliclazide—Nausea—Etoposide—prostate cancer	2.33e-05	0.000142	CcSEcCtD
Gliclazide—Hypertension—Epirubicin—prostate cancer	2.32e-05	0.000142	CcSEcCtD
Gliclazide—Hypersensitivity—Capecitabine—prostate cancer	2.32e-05	0.000142	CcSEcCtD
Gliclazide—Feeling abnormal—Prednisone—prostate cancer	2.31e-05	0.000141	CcSEcCtD
Gliclazide—Ill-defined disorder—Doxorubicin—prostate cancer	2.31e-05	0.000141	CcSEcCtD
Gliclazide—Pruritus—Docetaxel—prostate cancer	2.3e-05	0.000141	CcSEcCtD
Gliclazide—Anaemia—Doxorubicin—prostate cancer	2.3e-05	0.000141	CcSEcCtD
Gliclazide—Gastrointestinal pain—Prednisone—prostate cancer	2.3e-05	0.00014	CcSEcCtD
Gliclazide—Arthralgia—Epirubicin—prostate cancer	2.29e-05	0.00014	CcSEcCtD
Gliclazide—Myalgia—Epirubicin—prostate cancer	2.29e-05	0.00014	CcSEcCtD
Gliclazide—Chest pain—Epirubicin—prostate cancer	2.29e-05	0.00014	CcSEcCtD
Gliclazide—Agitation—Doxorubicin—prostate cancer	2.29e-05	0.00014	CcSEcCtD
Gliclazide—Anxiety—Epirubicin—prostate cancer	2.28e-05	0.00014	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.27e-05	0.000139	CcSEcCtD
Gliclazide—Discomfort—Epirubicin—prostate cancer	2.26e-05	0.000138	CcSEcCtD
Gliclazide—Asthenia—Capecitabine—prostate cancer	2.26e-05	0.000138	CcSEcCtD
Gliclazide—Malaise—Doxorubicin—prostate cancer	2.24e-05	0.000137	CcSEcCtD
Gliclazide—Dry mouth—Epirubicin—prostate cancer	2.24e-05	0.000137	CcSEcCtD
Gliclazide—Urticaria—Prednisone—prostate cancer	2.23e-05	0.000136	CcSEcCtD
Gliclazide—Pruritus—Capecitabine—prostate cancer	2.23e-05	0.000136	CcSEcCtD
Gliclazide—Leukopenia—Doxorubicin—prostate cancer	2.23e-05	0.000136	CcSEcCtD
Gliclazide—Diarrhoea—Docetaxel—prostate cancer	2.23e-05	0.000136	CcSEcCtD
Gliclazide—Body temperature increased—Prednisone—prostate cancer	2.22e-05	0.000136	CcSEcCtD
Gliclazide—Abdominal pain—Prednisone—prostate cancer	2.22e-05	0.000136	CcSEcCtD
Gliclazide—Confusional state—Epirubicin—prostate cancer	2.21e-05	0.000135	CcSEcCtD
Gliclazide—Palpitations—Doxorubicin—prostate cancer	2.2e-05	0.000134	CcSEcCtD
Gliclazide—Loss of consciousness—Doxorubicin—prostate cancer	2.19e-05	0.000134	CcSEcCtD
Gliclazide—Infection—Epirubicin—prostate cancer	2.18e-05	0.000133	CcSEcCtD
Gliclazide—Cough—Doxorubicin—prostate cancer	2.17e-05	0.000133	CcSEcCtD
Gliclazide—Convulsion—Doxorubicin—prostate cancer	2.16e-05	0.000132	CcSEcCtD
Gliclazide—Diarrhoea—Capecitabine—prostate cancer	2.16e-05	0.000132	CcSEcCtD
Gliclazide—Nervous system disorder—Epirubicin—prostate cancer	2.15e-05	0.000132	CcSEcCtD
Gliclazide—Dizziness—Docetaxel—prostate cancer	2.15e-05	0.000132	CcSEcCtD
Gliclazide—Thrombocytopenia—Epirubicin—prostate cancer	2.15e-05	0.000131	CcSEcCtD
Gliclazide—Hypertension—Doxorubicin—prostate cancer	2.15e-05	0.000131	CcSEcCtD
Gliclazide—Tachycardia—Epirubicin—prostate cancer	2.14e-05	0.000131	CcSEcCtD
Gliclazide—Skin disorder—Epirubicin—prostate cancer	2.13e-05	0.00013	CcSEcCtD
Gliclazide—Hyperhidrosis—Epirubicin—prostate cancer	2.12e-05	0.00013	CcSEcCtD
Gliclazide—Myalgia—Doxorubicin—prostate cancer	2.12e-05	0.00013	CcSEcCtD
Gliclazide—Chest pain—Doxorubicin—prostate cancer	2.12e-05	0.00013	CcSEcCtD
Gliclazide—Arthralgia—Doxorubicin—prostate cancer	2.12e-05	0.00013	CcSEcCtD
Gliclazide—Anxiety—Doxorubicin—prostate cancer	2.11e-05	0.000129	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.1e-05	0.000129	CcSEcCtD
Gliclazide—Discomfort—Doxorubicin—prostate cancer	2.09e-05	0.000128	CcSEcCtD
Gliclazide—Dizziness—Capecitabine—prostate cancer	2.08e-05	0.000127	CcSEcCtD
Gliclazide—Dry mouth—Doxorubicin—prostate cancer	2.07e-05	0.000127	CcSEcCtD
Gliclazide—Vomiting—Docetaxel—prostate cancer	2.07e-05	0.000127	CcSEcCtD
Gliclazide—Hypersensitivity—Prednisone—prostate cancer	2.07e-05	0.000126	CcSEcCtD
Gliclazide—Rash—Docetaxel—prostate cancer	2.05e-05	0.000125	CcSEcCtD
Gliclazide—Hypotension—Epirubicin—prostate cancer	2.05e-05	0.000125	CcSEcCtD
Gliclazide—Dermatitis—Docetaxel—prostate cancer	2.05e-05	0.000125	CcSEcCtD
Gliclazide—Confusional state—Doxorubicin—prostate cancer	2.05e-05	0.000125	CcSEcCtD
Gliclazide—Headache—Docetaxel—prostate cancer	2.04e-05	0.000125	CcSEcCtD
Gliclazide—Infection—Doxorubicin—prostate cancer	2.02e-05	0.000123	CcSEcCtD
Gliclazide—Asthenia—Prednisone—prostate cancer	2.01e-05	0.000123	CcSEcCtD
Gliclazide—Vomiting—Capecitabine—prostate cancer	2e-05	0.000122	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Epirubicin—prostate cancer	2e-05	0.000122	CcSEcCtD
Gliclazide—Nervous system disorder—Doxorubicin—prostate cancer	1.99e-05	0.000122	CcSEcCtD
Gliclazide—Thrombocytopenia—Doxorubicin—prostate cancer	1.99e-05	0.000122	CcSEcCtD
Gliclazide—Rash—Capecitabine—prostate cancer	1.99e-05	0.000121	CcSEcCtD
Gliclazide—Pruritus—Prednisone—prostate cancer	1.99e-05	0.000121	CcSEcCtD
Gliclazide—Insomnia—Epirubicin—prostate cancer	1.99e-05	0.000121	CcSEcCtD
Gliclazide—Dermatitis—Capecitabine—prostate cancer	1.99e-05	0.000121	CcSEcCtD
Gliclazide—Tachycardia—Doxorubicin—prostate cancer	1.98e-05	0.000121	CcSEcCtD
Gliclazide—Headache—Capecitabine—prostate cancer	1.97e-05	0.000121	CcSEcCtD
Gliclazide—Skin disorder—Doxorubicin—prostate cancer	1.97e-05	0.000121	CcSEcCtD
Gliclazide—Paraesthesia—Epirubicin—prostate cancer	1.97e-05	0.000121	CcSEcCtD
Gliclazide—Hyperhidrosis—Doxorubicin—prostate cancer	1.96e-05	0.00012	CcSEcCtD
Gliclazide—Dyspnoea—Epirubicin—prostate cancer	1.96e-05	0.00012	CcSEcCtD
Gliclazide—Somnolence—Epirubicin—prostate cancer	1.95e-05	0.000119	CcSEcCtD
Gliclazide—Nausea—Docetaxel—prostate cancer	1.93e-05	0.000118	CcSEcCtD
Gliclazide—Dyspepsia—Epirubicin—prostate cancer	1.93e-05	0.000118	CcSEcCtD
Gliclazide—Diarrhoea—Prednisone—prostate cancer	1.92e-05	0.000117	CcSEcCtD
Gliclazide—Hypotension—Doxorubicin—prostate cancer	1.9e-05	0.000116	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Epirubicin—prostate cancer	1.9e-05	0.000116	CcSEcCtD
Gliclazide—Fatigue—Epirubicin—prostate cancer	1.89e-05	0.000116	CcSEcCtD
Gliclazide—Pain—Epirubicin—prostate cancer	1.88e-05	0.000115	CcSEcCtD
Gliclazide—Constipation—Epirubicin—prostate cancer	1.88e-05	0.000115	CcSEcCtD
Gliclazide—Nausea—Capecitabine—prostate cancer	1.87e-05	0.000114	CcSEcCtD
Gliclazide—Dizziness—Prednisone—prostate cancer	1.86e-05	0.000113	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.85e-05	0.000113	CcSEcCtD
Gliclazide—Insomnia—Doxorubicin—prostate cancer	1.84e-05	0.000112	CcSEcCtD
Gliclazide—Paraesthesia—Doxorubicin—prostate cancer	1.82e-05	0.000112	CcSEcCtD
Gliclazide—Dyspnoea—Doxorubicin—prostate cancer	1.81e-05	0.000111	CcSEcCtD
Gliclazide—Feeling abnormal—Epirubicin—prostate cancer	1.81e-05	0.000111	CcSEcCtD
Gliclazide—Somnolence—Doxorubicin—prostate cancer	1.81e-05	0.00011	CcSEcCtD
Gliclazide—Gastrointestinal pain—Epirubicin—prostate cancer	1.8e-05	0.00011	CcSEcCtD
Gliclazide—Dyspepsia—Doxorubicin—prostate cancer	1.79e-05	0.000109	CcSEcCtD
Gliclazide—Vomiting—Prednisone—prostate cancer	1.78e-05	0.000109	CcSEcCtD
Gliclazide—Rash—Prednisone—prostate cancer	1.77e-05	0.000108	CcSEcCtD
Gliclazide—Dermatitis—Prednisone—prostate cancer	1.77e-05	0.000108	CcSEcCtD
Gliclazide—Headache—Prednisone—prostate cancer	1.76e-05	0.000107	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.75e-05	0.000107	CcSEcCtD
Gliclazide—Fatigue—Doxorubicin—prostate cancer	1.75e-05	0.000107	CcSEcCtD
Gliclazide—Urticaria—Epirubicin—prostate cancer	1.74e-05	0.000107	CcSEcCtD
Gliclazide—Pain—Doxorubicin—prostate cancer	1.74e-05	0.000106	CcSEcCtD
Gliclazide—Constipation—Doxorubicin—prostate cancer	1.74e-05	0.000106	CcSEcCtD
Gliclazide—Body temperature increased—Epirubicin—prostate cancer	1.74e-05	0.000106	CcSEcCtD
Gliclazide—Abdominal pain—Epirubicin—prostate cancer	1.74e-05	0.000106	CcSEcCtD
Gliclazide—Feeling abnormal—Doxorubicin—prostate cancer	1.67e-05	0.000102	CcSEcCtD
Gliclazide—Nausea—Prednisone—prostate cancer	1.67e-05	0.000102	CcSEcCtD
Gliclazide—Gastrointestinal pain—Doxorubicin—prostate cancer	1.66e-05	0.000102	CcSEcCtD
Gliclazide—Hypersensitivity—Epirubicin—prostate cancer	1.62e-05	9.89e-05	CcSEcCtD
Gliclazide—Urticaria—Doxorubicin—prostate cancer	1.61e-05	9.86e-05	CcSEcCtD
Gliclazide—Body temperature increased—Doxorubicin—prostate cancer	1.61e-05	9.82e-05	CcSEcCtD
Gliclazide—Abdominal pain—Doxorubicin—prostate cancer	1.61e-05	9.82e-05	CcSEcCtD
Gliclazide—Asthenia—Epirubicin—prostate cancer	1.58e-05	9.63e-05	CcSEcCtD
Gliclazide—Pruritus—Epirubicin—prostate cancer	1.55e-05	9.5e-05	CcSEcCtD
Gliclazide—Diarrhoea—Epirubicin—prostate cancer	1.5e-05	9.18e-05	CcSEcCtD
Gliclazide—Hypersensitivity—Doxorubicin—prostate cancer	1.5e-05	9.15e-05	CcSEcCtD
Gliclazide—Asthenia—Doxorubicin—prostate cancer	1.46e-05	8.91e-05	CcSEcCtD
Gliclazide—Dizziness—Epirubicin—prostate cancer	1.45e-05	8.87e-05	CcSEcCtD
Gliclazide—Pruritus—Doxorubicin—prostate cancer	1.44e-05	8.79e-05	CcSEcCtD
Gliclazide—Vomiting—Epirubicin—prostate cancer	1.4e-05	8.53e-05	CcSEcCtD
Gliclazide—Diarrhoea—Doxorubicin—prostate cancer	1.39e-05	8.5e-05	CcSEcCtD
Gliclazide—Rash—Epirubicin—prostate cancer	1.38e-05	8.46e-05	CcSEcCtD
Gliclazide—Dermatitis—Epirubicin—prostate cancer	1.38e-05	8.45e-05	CcSEcCtD
Gliclazide—Headache—Epirubicin—prostate cancer	1.38e-05	8.41e-05	CcSEcCtD
Gliclazide—Dizziness—Doxorubicin—prostate cancer	1.34e-05	8.21e-05	CcSEcCtD
Gliclazide—Nausea—Epirubicin—prostate cancer	1.3e-05	7.97e-05	CcSEcCtD
Gliclazide—Vomiting—Doxorubicin—prostate cancer	1.29e-05	7.9e-05	CcSEcCtD
Gliclazide—Rash—Doxorubicin—prostate cancer	1.28e-05	7.83e-05	CcSEcCtD
Gliclazide—Dermatitis—Doxorubicin—prostate cancer	1.28e-05	7.82e-05	CcSEcCtD
Gliclazide—Headache—Doxorubicin—prostate cancer	1.27e-05	7.78e-05	CcSEcCtD
Gliclazide—Nausea—Doxorubicin—prostate cancer	1.21e-05	7.38e-05	CcSEcCtD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—LPL—prostate cancer	5.31e-06	5.14e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTA4—prostate cancer	5.25e-06	5.08e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TBXAS1—prostate cancer	5.25e-06	5.08e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—MED12—prostate cancer	5.23e-06	5.06e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CB—prostate cancer	5.2e-06	5.03e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GNG5—prostate cancer	5.19e-06	5.02e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—APC—prostate cancer	5.18e-06	5.01e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CG—prostate cancer	5.18e-06	5.01e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS2—prostate cancer	5.15e-06	4.98e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	5.15e-06	4.98e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—LRP2—prostate cancer	5.13e-06	4.96e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PLCB2—prostate cancer	5.13e-06	4.96e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP2C18—prostate cancer	5.13e-06	4.96e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	5.13e-06	4.96e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EGF—prostate cancer	5.12e-06	4.95e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IRS1—prostate cancer	5.12e-06	4.95e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTA2—prostate cancer	5.12e-06	4.95e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ABCG5—prostate cancer	5.05e-06	4.89e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SULT1A1—prostate cancer	5.05e-06	4.89e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CB—prostate cancer	5.04e-06	4.87e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—P4HB—prostate cancer	5.03e-06	4.87e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CREBBP—prostate cancer	5e-06	4.84e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NCOA3—prostate cancer	5e-06	4.83e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—prostate cancer	4.99e-06	4.83e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GSK3B—prostate cancer	4.97e-06	4.81e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IGF1—prostate cancer	4.94e-06	4.78e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTA1—prostate cancer	4.93e-06	4.77e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	4.91e-06	4.75e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—INS—prostate cancer	4.9e-06	4.74e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC22A1—prostate cancer	4.89e-06	4.74e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CA—prostate cancer	4.89e-06	4.73e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NAT2—prostate cancer	4.88e-06	4.72e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTO1—prostate cancer	4.88e-06	4.72e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HSD3B2—prostate cancer	4.88e-06	4.72e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	4.84e-06	4.68e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CREBBP—prostate cancer	4.8e-06	4.65e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SULT2A1—prostate cancer	4.77e-06	4.62e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—HPGDS—prostate cancer	4.77e-06	4.61e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IGF1—prostate cancer	4.74e-06	4.59e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CD—prostate cancer	4.74e-06	4.59e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP2C19—prostate cancer	4.74e-06	4.58e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—MED12—prostate cancer	4.69e-06	4.54e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	4.69e-06	4.54e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SERPINE1—prostate cancer	4.69e-06	4.54e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PLCB2—prostate cancer	4.68e-06	4.53e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—LRP2—prostate cancer	4.68e-06	4.53e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP2C18—prostate cancer	4.68e-06	4.53e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GNG5—prostate cancer	4.66e-06	4.5e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTT1—prostate cancer	4.62e-06	4.47e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ACHE—prostate cancer	4.62e-06	4.47e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—P4HB—prostate cancer	4.59e-06	4.44e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAP2K1—prostate cancer	4.58e-06	4.44e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP2A6—prostate cancer	4.57e-06	4.42e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CD—prostate cancer	4.55e-06	4.41e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	4.55e-06	4.4e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SERPINE1—prostate cancer	4.5e-06	4.36e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTEN—prostate cancer	4.49e-06	4.34e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NCOA3—prostate cancer	4.48e-06	4.34e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NOS3—prostate cancer	4.48e-06	4.33e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC22A1—prostate cancer	4.46e-06	4.32e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKR1C3—prostate cancer	4.44e-06	4.3e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PRKACB—prostate cancer	4.42e-06	4.28e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	4.41e-06	4.27e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	4.41e-06	4.26e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP17A1—prostate cancer	4.38e-06	4.23e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FGF2—prostate cancer	4.36e-06	4.22e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTEN—prostate cancer	4.35e-06	4.21e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—JAK2—prostate cancer	4.35e-06	4.21e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SULT2A1—prostate cancer	4.35e-06	4.21e-05	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—CREBBP—prostate cancer	4.33e-06	4.19e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	4.32e-06	4.18e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NOS3—prostate cancer	4.3e-06	4.16e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—EP300—prostate cancer	4.28e-06	4.14e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—MED12—prostate cancer	4.28e-06	4.14e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HPGDS—prostate cancer	4.28e-06	4.14e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GNG5—prostate cancer	4.25e-06	4.11e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—JAK2—prostate cancer	4.18e-06	4.04e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NCOA2—prostate cancer	4.17e-06	4.03e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—EP300—prostate cancer	4.15e-06	4.02e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ACHE—prostate cancer	4.15e-06	4.02e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTT1—prostate cancer	4.15e-06	4.02e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CB—prostate cancer	4.13e-06	4e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP2A6—prostate cancer	4.1e-06	3.97e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NCOA3—prostate cancer	4.09e-06	3.96e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	4.09e-06	3.95e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MDM2—prostate cancer	4.08e-06	3.95e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ERBB2—prostate cancer	4.02e-06	3.89e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	4.02e-06	3.89e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—AKT1—prostate cancer	3.99e-06	3.86e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKR1C3—prostate cancer	3.99e-06	3.86e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SLC5A5—prostate cancer	3.98e-06	3.85e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CB—prostate cancer	3.97e-06	3.84e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PRKACB—prostate cancer	3.97e-06	3.84e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP17A1—prostate cancer	3.93e-06	3.8e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HPGDS—prostate cancer	3.9e-06	3.77e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP2E1—prostate cancer	3.89e-06	3.76e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP2C19—prostate cancer	3.88e-06	3.75e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	3.87e-06	3.75e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NQO1—prostate cancer	3.84e-06	3.72e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCL8—prostate cancer	3.81e-06	3.69e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IL2—prostate cancer	3.79e-06	3.67e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TH—prostate cancer	3.79e-06	3.66e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTT1—prostate cancer	3.78e-06	3.66e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ACHE—prostate cancer	3.78e-06	3.66e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	3.76e-06	3.64e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP3A4—prostate cancer	3.75e-06	3.62e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NCOA2—prostate cancer	3.74e-06	3.62e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP2A6—prostate cancer	3.74e-06	3.62e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.73e-06	3.61e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	3.73e-06	3.6e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1B—prostate cancer	3.72e-06	3.6e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP1B1—prostate cancer	3.68e-06	3.56e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CASP3—prostate cancer	3.65e-06	3.53e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL2—prostate cancer	3.65e-06	3.53e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKR1C3—prostate cancer	3.64e-06	3.52e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PRKACB—prostate cancer	3.62e-06	3.5e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP17A1—prostate cancer	3.58e-06	3.47e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC5A5—prostate cancer	3.57e-06	3.45e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GGT1—prostate cancer	3.57e-06	3.45e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCND1—prostate cancer	3.55e-06	3.44e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	3.53e-06	3.42e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CTNNB1—prostate cancer	3.52e-06	3.4e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NCOA1—prostate cancer	3.51e-06	3.4e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP2E1—prostate cancer	3.49e-06	3.37e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP19A1—prostate cancer	3.46e-06	3.35e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP9—prostate cancer	3.45e-06	3.34e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NQO1—prostate cancer	3.45e-06	3.34e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1A—prostate cancer	3.44e-06	3.33e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTEN—prostate cancer	3.43e-06	3.32e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NCOA2—prostate cancer	3.41e-06	3.3e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—EP300—prostate cancer	3.4e-06	3.29e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TH—prostate cancer	3.4e-06	3.29e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	3.38e-06	3.27e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP3A4—prostate cancer	3.36e-06	3.25e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.35e-06	3.24e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—RXRA—prostate cancer	3.34e-06	3.23e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SRC—prostate cancer	3.31e-06	3.2e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP1B1—prostate cancer	3.31e-06	3.2e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EP300—prostate cancer	3.27e-06	3.16e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC5A5—prostate cancer	3.26e-06	3.15e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.25e-06	3.15e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—prostate cancer	3.22e-06	3.12e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—COMT—prostate cancer	3.22e-06	3.11e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTP1—prostate cancer	3.2e-06	3.1e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GGT1—prostate cancer	3.2e-06	3.1e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SRC—prostate cancer	3.18e-06	3.08e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP2E1—prostate cancer	3.18e-06	3.08e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CA—prostate cancer	3.17e-06	3.06e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NCOA1—prostate cancer	3.15e-06	3.05e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ITPR1—prostate cancer	3.15e-06	3.05e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NQO1—prostate cancer	3.14e-06	3.04e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP19A1—prostate cancer	3.11e-06	3.01e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.1e-06	3e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TH—prostate cancer	3.1e-06	3e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	3.08e-06	2.98e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CA—prostate cancer	3.07e-06	2.97e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—STAT3—prostate cancer	3.07e-06	2.97e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP3A4—prostate cancer	3.07e-06	2.97e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.05e-06	2.95e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP1B1—prostate cancer	3.01e-06	2.92e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—RXRA—prostate cancer	3e-06	2.9e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TYMS—prostate cancer	2.98e-06	2.88e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TGFB1—prostate cancer	2.96e-06	2.86e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTM1—prostate cancer	2.94e-06	2.85e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GGT1—prostate cancer	2.92e-06	2.82e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.92e-06	2.82e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—LPL—prostate cancer	2.89e-06	2.8e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—COMT—prostate cancer	2.89e-06	2.8e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTP1—prostate cancer	2.88e-06	2.78e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NCOA1—prostate cancer	2.88e-06	2.78e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MYC—prostate cancer	2.85e-06	2.76e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TGFB1—prostate cancer	2.84e-06	2.75e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP19A1—prostate cancer	2.83e-06	2.74e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ITPR1—prostate cancer	2.83e-06	2.74e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP1A1—prostate cancer	2.79e-06	2.7e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EGFR—prostate cancer	2.79e-06	2.7e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.78e-06	2.69e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ERCC2—prostate cancer	2.77e-06	2.68e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—KRAS—prostate cancer	2.74e-06	2.65e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—RXRA—prostate cancer	2.74e-06	2.65e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TYMS—prostate cancer	2.67e-06	2.59e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.66e-06	2.57e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTM1—prostate cancer	2.64e-06	2.56e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—COMT—prostate cancer	2.64e-06	2.55e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KRAS—prostate cancer	2.63e-06	2.55e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTP1—prostate cancer	2.62e-06	2.54e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—MTHFR—prostate cancer	2.6e-06	2.52e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—LPL—prostate cancer	2.59e-06	2.51e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AKT1—prostate cancer	2.59e-06	2.5e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ITPR1—prostate cancer	2.58e-06	2.5e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPARA—prostate cancer	2.55e-06	2.47e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.54e-06	2.46e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CA—prostate cancer	2.52e-06	2.44e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AKT1—prostate cancer	2.51e-06	2.43e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP1A1—prostate cancer	2.51e-06	2.42e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ERCC2—prostate cancer	2.49e-06	2.4e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TYMS—prostate cancer	2.44e-06	2.36e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—prostate cancer	2.44e-06	2.36e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CA—prostate cancer	2.42e-06	2.34e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTM1—prostate cancer	2.41e-06	2.33e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CAV1—prostate cancer	2.4e-06	2.32e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—LPL—prostate cancer	2.37e-06	2.29e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—prostate cancer	2.34e-06	2.26e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—MTHFR—prostate cancer	2.34e-06	2.26e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.29e-06	2.22e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPARA—prostate cancer	2.29e-06	2.22e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP1A1—prostate cancer	2.28e-06	2.21e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ERCC2—prostate cancer	2.27e-06	2.19e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CG—prostate cancer	2.19e-06	2.12e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CAV1—prostate cancer	2.15e-06	2.08e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6—prostate cancer	2.14e-06	2.07e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—MTHFR—prostate cancer	2.13e-06	2.06e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPARA—prostate cancer	2.09e-06	2.02e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—INS—prostate cancer	2.07e-06	2e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.06e-06	1.99e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—AKT1—prostate cancer	2.06e-06	1.99e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CREBBP—prostate cancer	2.03e-06	1.96e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKT1—prostate cancer	1.98e-06	1.91e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CAV1—prostate cancer	1.96e-06	1.9e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CG—prostate cancer	1.96e-06	1.9e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CD—prostate cancer	1.92e-06	1.86e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.88e-06	1.82e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—INS—prostate cancer	1.86e-06	1.8e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CREBBP—prostate cancer	1.82e-06	1.76e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NOS3—prostate cancer	1.81e-06	1.76e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CG—prostate cancer	1.79e-06	1.73e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CD—prostate cancer	1.73e-06	1.67e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—INS—prostate cancer	1.69e-06	1.64e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CB—prostate cancer	1.68e-06	1.62e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—prostate cancer	1.66e-06	1.61e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CREBBP—prostate cancer	1.66e-06	1.61e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NOS3—prostate cancer	1.63e-06	1.58e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CD—prostate cancer	1.57e-06	1.52e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CB—prostate cancer	1.5e-06	1.46e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—prostate cancer	1.49e-06	1.44e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NOS3—prostate cancer	1.49e-06	1.44e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTEN—prostate cancer	1.45e-06	1.4e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—EP300—prostate cancer	1.38e-06	1.34e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CB—prostate cancer	1.37e-06	1.33e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—prostate cancer	1.36e-06	1.31e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTEN—prostate cancer	1.3e-06	1.26e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—EP300—prostate cancer	1.24e-06	1.2e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTEN—prostate cancer	1.18e-06	1.15e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—EP300—prostate cancer	1.13e-06	1.09e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CA—prostate cancer	1.02e-06	9.88e-06	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CA—prostate cancer	9.17e-07	8.87e-06	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CA—prostate cancer	8.36e-07	8.09e-06	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKT1—prostate cancer	8.34e-07	8.07e-06	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKT1—prostate cancer	7.49e-07	7.25e-06	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKT1—prostate cancer	6.83e-07	6.61e-06	CbGpPWpGaD
